Pharmacokinetics and brain distribution differences of baicalin in rat underlying the effect of Panax notoginsenosides after intravenous administration.
10.1016/S1875-5364(14)60097-2
- Author:
Yan-Fang YANG
1
,
2
;
Zhi LI
1
,
3
,
4
;
Wen-Feng XIN
5
;
Yong-Yan WANG
4
,
6
;
Wen-Sheng ZHANG
1
,
3
,
7
,
8
Author Information
1. State Key Laboratory of Earth Surface Processes and Resource Ecology, Beijing Normal University, Beijing 100875, China
2. School of Pharmaceutical Science, Peking University, Beijing 100191, China.
3. Engineering Research Center of Natural Medicine, Ministry of Education, Beijing 100875, China
4. College of Resources Science & Technology, Beijing Normal University, Beijing 100875, China.
5. Engineering Research Center of Sanqi Biotechnology and Pharmaceutical, Kunming 650000, China.
6. Engineering Research Center of Natural Medicine, Ministry of Education, Beijing 100875, China
7. College of Resources Science & Technology, Beijing Normal University, Beijing 100875, China
8. Engineering Research Center of Sanqi Biotechnology and Pharmaceutical, Kunming 650000, China. Electronic address: zws@bnu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Baicalin;
HPLC/MS/MS;
Panax notoginsenosides;
Pharmacokinetics;
Rat brain;
Rat plasma
- MeSH:
Administration, Intravenous;
Animals;
Area Under Curve;
Brain;
metabolism;
Brain Diseases;
drug therapy;
Chromatography, High Pressure Liquid;
Drug Synergism;
Flavonoids;
metabolism;
pharmacokinetics;
therapeutic use;
Ginsenosides;
pharmacology;
Injections, Intravenous;
Male;
Panax notoginseng;
chemistry;
Phytotherapy;
Plant Extracts;
metabolism;
pharmacokinetics;
pharmacology;
Plant Roots;
Rats, Wistar;
Scutellaria baicalensis;
chemistry;
Tandem Mass Spectrometry
- From:
Chinese Journal of Natural Medicines (English Ed.)
2014;12(8):632-640
- CountryChina
- Language:English
-
Abstract:
Baicalin (BA) is the most well-known flavonoid present in Radix Scutellariae. The aim of this study was to explore whether the pharmacokinetic behavior of BA in rat brain can be affected by Panax notoginsenosides (PNS), and to assess the possible mechanism for the observed effects. Specific HPLC and HPLC/MS/MS methods were developed and validated for the determination of BA in the rat plasma and brain using carbamazepine as an internal standard. BA was found to enter rat brain quickly after a single intravenous dose. When co-administered with PNS, clearance (CL) of BA from rat plasma decreased by 50.00%, while the area under the curve AUC0-t and AUC0-∞ increased 94.69% and 87.68%, respectively. On the other hand, some pharmacokinetic parameters of BA in rat brain had obvious differences after PNS was administered, such as an increase in Tmax from 5 min to 15 min, an increase in AUC0-t and AUC0-∞ by 42.75% and 29.39%, respectively, as well as a decrease in CL by 27.95%. Together, these results indicate that PNS can decrease the elimination rate of BA from rat plasma, promote the penetration of BA into rat brain, increase the concentration and slow down the elimination of BA from rat brain. The data provide important information that compatibility with PNS can promote the consequent effects of BA for the treatment of encephalopathy.
